How does an investor profit if a company has the best technology in the
world, but can't deliver market-beating returns? That's probably a harsh
intro for
Hologic (Nasdaq:
HOLX)
today, but the fact remains that the company has to demonstrate that it
can drive tomosynthesis adoption and solid growth in diagnostics for
this stock to really work over the coming years. That puts the shares in
a challenging place for investors; bulls can likely see a lot of value
here, while bears will point to the high debt and oncoming competition
and likely conclude that the shares are best avoided for now.
Please click the link to continue:
http://www.investopedia.com/stock-analysis/2012/Time-For-Hologic-To-Translate-Technology-Into-Results-HOLX-GE-CPHD-BDX1114.aspx
No comments:
Post a Comment